Serine 727 phosphorylation of STAT3: An early change in mouse hepatocarcinogenesis induced by neonatal treatment with diethylnitrosamine

Molecular Carcinogenesis

Volumn 53, Issue 1, 2014, Pages 67-76

  Miyakoshi, Masaaki ^a   Yamamoto, Masahiro ^a   Tanaka, Hiroki ^a,b   Ogawa, Katsuhiro ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

Author keywords

Hepatocarcinogenesis; Preneoplastic hepatocytes; S727 phosphorylation; STAT3; Y705 phosphorylation

Indexed keywords

DIETHYLNITROSAMINE; INTERLEUKIN 6; JANUS KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN KINASE B; SERINE; SERINE 727; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; HISTOPATHOLOGY; IN VITRO STUDY; INFLAMMATORY CELL; LIVER CARCINOGENESIS; LIVER CELL; LIVER INJURY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WILD TYPE;

BOVINAE; MUS;

EID: 84890427346     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.21949     Document Type: Article

References (43)

1. Tabor E. Hepatocellular carcinoma: global epidemiology. Dig Liver Dis 2001; 132:2557-2576.
2. Nordenstedt H, White DJ, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010; 42S:S206-S214.
3. Ogawa K. Molecular pathology of early stage chemically induced hepatocarcinogenesis. Pathol Int 2009; 59:605-622.
4. Darnell JE Jr. Validating Stat3 in cancer therapy. Nat Med 2005; 11:595-596.
5. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009; 9:798-809.
6. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3:651-662.
7. Decker T, Kovarik P. Serine phosphorylation of STATs. Oncogene 2000; 19:2628-2637.
8. Yang J, Stark GR. Roles of unphosphorylated STATs in signaling. Cell Res 2008; 18:443-451.
9. Grivennikov S, Karin M. Dangerous liaisons:STAT3 and NF-κB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 2010; 21:11-19.
10. Liu Y, Li PK, Li C, Lin J. Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells. J Biol Chem 2010; 285:27429-27439.
11. Li WC, Ye SL, Sun RX, et al. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense orligonucleotide targeting signal transducer and activator of transcription 3. Clin Cancer Res 2006; 12:7140-7148.
12. Kusaba M, Nakao K, Goto T, et al. Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-medicated apoptosis. J Hepatol 2007; 47:546-555.
13. Maione D, Carlo ED, Li W, et al. Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EMBO J 1998; 17:5588-5597.
14. Ogata H, Kobayashi T, Chinen T, et al. Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology 2006; 131:179-193.
15. Riehle KJ, Campbell JS, McMahan RS, et al. Regulation of liver regeneration and hepatocarcinogenesis by suppressor of cytokine signaling 3. J Exp Med 2008; 205:91-103.
16. Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317:121-124.
17. Rebouissou S, Amessou M, Couchy G, et al. Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumors. Nature 2009; 457:200-204.
18. Pilati C, Amessou M, Bihl MP, et al. Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. J Exp Med 2011; 208:1359-1366.
19. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140:883-899.
20. Wang H, Lafdil F, Kong X, Gao B. Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target. Int J Biol Sci 2011; 7:536-550.
21. Park EJ, Lee JH, Yu GY, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140:197-208.
22. He G, Yu GY, Temkin V, et al. Hepatocyte IKKβ/NF-κB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell 2010; 17:286-297.
23. Maeda S, Kamata H, Luo JL, Leffert H, Karin M. IKKβ couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005; 121:977-990.
24. Luedde T, Beraza N, Kotsikris V, et al. Deletion of NEMO/IKKγ in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell 2007; 11:119-132.
25. Bard-Chapeau EA, Li S, Ding J, et al. Ptpn11/Shp2 acts as tumor suppressor in hepatocellular carcinogenesis. Cancer Cell 2011; 19:629-639.
26. Haybaek J, Zeller N, Wolf MJ, et al. A lymphotoxin-driven pathway to hepatocelllar carcinoma. Cancer Cell 2009; 16:295-308.
27. Machida K, Tsukamoto H, Liu JC, et al. C-Jun mediates HCV hepatocarcinogenesis through STAT3 and nitric oxide-dependent impairment of oxidative DNA repair. Hepatology 2010; 52:480-492.
28. Vesselinovitch SD. Perinatal mouse liver carcinogenesis as a sensitive carcinogenesis model and the role of the sex hormonal environment in tumor development. Prog Clin Biol Res 1990; 331:53-68.
29. Thoolen B, Maronpot RR, Harada T, et al. Proliferative and nonproliferative lesions of the rat and mouse hepatobiliary system. Toxicol Pathol 2010; 38:5S-81S.
30. Yamamoto M, Tamakawa S, Yoshie M, Yaginuma Y, Ogawa K. Neoplastic hepatocyte growth associated with cyclin D1 redistribution from the cytoplasm to the nucleus in mouse hepatocarcinogenesis. Mol Carcinog 2006; 45:901-913.
31. Tanaka H, Yamamoto M, Hashimoto N, et al. Hypoxia-independent overexpression of hypoxia-inducible factor 1α as an early change in mouse hepatocarcinogenesis. Cancer Res 2006; 66:11263-11270.
32. Qin HR, Kim HJ, Kim JY, et al. Activation of signal transducer and activator of transcription 3 through a phosphomimetic serine 727 promotes prostate tumorigenesis independent of tyrosine 705 phosphorylation. Cancer Res 2008; 68:7736-7741.
33. Valdembri D, Serini G, Vacca A, Ribattu D, Bussolino F. In vivo activation of JAK2/STAT-3 pathway during angiogenesis induced by GM-CSF. FASEB J 2002; 16:225-227.
34. O'Rourke L, Shepherd PR. Biphasic regulation of extracellular-signal-regulated protein kinase by leptin in macrophages: role in regulating STAT3 Ser727 phosphorylation and DNA binding. Biochem J 2002; 364:875-879.
35. Cerera BP, Pressin JE. Insulin stimulates the serine phosphorylation of the signal transducer and activator of transcription (STAT3) isoform. J Biol Chem 1996; 271:12121-12124.
36. Zong CS, Chan J, Levy DE, et al. Mechanism of STAT3 activation by insulin-like growth factor I receptor. J Biol Chem 2000; 275:15099-15105.
37. Soresi M, Giannitrapani L, D'Antona F, et al. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol 2006; 12:2563-2568.
38. Liu H, Ma Y, Cole SM, et al. Serine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survival. Blood 2003; 102:344-352.
39. Shen Y, Schlessinger K, Zhu X, et al. Essential role of STAT3 in postnatal survival and growth revealed by mice lacking STAT3 serine phosphorylation. Mol Cell Biol 2004; 24:407-419.
40. Androutsellis-Theotokis A, Leker RR, Soldner F. Notch signaling regulates stem cell numbers in vitro and in vivo. Nature 2006; 442:823-826.
41. Kim JH, Yoon MS, Chen J. Signal transducer and activator of transcription 3 (STAT3) mediates amino acid inhibition of insulin signaling through serine 727 phosphorylation. J Biol Chem 2009; 284:35425-35432.
42. Reich NC, Liu L. Tracking STAT nuclear traffic. Nat Rev Immnol 2006; 6:602-612.
43. Meyer T, Gavenis K, Vinkemeier U. Cell type-specific and tyrosine phosphorylation-independent nuclear presence of STAT1 and STAT3. Exp Cell Res 2002; 272:45-55.